Physician profile
Bahman Bandari
NPI 1083615298
$1,564.16
in general payments reported to CMS, 2019-2025
14 companies · $267 in 2025
The $267 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $188 · 2020: $125 · 2021: $441 · 2022: $86.12 · 2023: $458 · 2025: $267.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $725.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $724.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $288.91 | 2019-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $166.62 | 2021 | |
| Boston Scientific Corporation | $147.62 | 2025 | Farapulse |
| Medtronic, INC. | $141.64 | 2023 | Ligasure |
| Intuitive Surgical, INC. | $133.12 | 2023 | Da Vinci Surgical System |
| Alexion Pharmaceuticals, INC. | $125.00 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $120.28 | 2023 | Jardiance |
| Gilead Sciences, INC. | $119.41 | 2025 | Yeztugo |
| Biogen, INC. | $88.12 | 2021 | |
| Novo Nordisk INC | $69.86 | 2019 | |
| Conmed Corporation | $62.50 | 2023 | Airseal |
| Abbott Laboratories | $54.68 | 2022 | |
| Dexcom, INC. | $31.44 | 2022 | |
| Merck Sharp & Dohme LLC | $14.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bahman Bandari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.